(NAS = New Active Substance)
Anaesthetic sedative NAS
Local anaesthesia
Acute ischaemic stroke NAS
Cardioplegia
Cardiovascular disease prophylaxis
Dyslipidaemia NASs
Abuse deterrence
Breakthrough pain
Central neuroprotectant NAS
Hypnotics
Mania NAS
Migraine
Multiple sclerosis NASs
and biosimilar
Novel antidepressant NAS
Opioid dependence
Parkinson’s disease NAS
Parkinson’s disease new formulation
Schizophrenia NAS
Sensory neuropathy NAS
Strong analgesics
Antihistamines
Atopic dermatitis NAS
Hereditary angio-oedema NAS
Pruritus NAS
Psoriasis NASs
Topical steroid bioequivalence
Acromegaly
Familial adenomatous polyposis
Male hypogonadism
PTH
Topical postmenopausal therapy
Type 2 Diabetes – NASs & combination therapy
Chronic anal fissure NAS
Faecal incontinence
Gastric acid suppression
Gastric antisecretory agent NAS
GLP-1 analogue NAS
Anaemia - NASs & Biosimilars
Autoimmune Haemolytic anaemia NAS
Heparin-induced thrombocytopenia NAS
Paroxysmal Nocturnal Haemoglobinuria NAS
Antifungal agents
Broad spectrum antifungals
Generic antibacterial agents
Herpes simplex NAS
Acute leukaemias; lymphoblastic / myeloid NASs
Early breast cancer
Hepatobiliary cancers
Malignant melanoma NAS
Malignant pleural mesothelioma NAS
Multiple myeloma
Prostate cancer NAS
Tumour suppression
Complex generics
Liposomal biosimilars
Modified release products
Therapeutic equivalence /
non-inferiority studies
Topical product development
Asthma NAS/combinations
COPD NAS/combinations
Large molecule inhalation for serious pulmonary disease
Anaphylaxis
Drooling
Electrolye imbalance NAS
Herbals
Hyperhidrosis
Hyperphosphataemia NAS
Immune nephropathies NAS
Induction of labour
Macular Degeneration NAS
Poisoning
Rheumatoid arthritis NAS
Vaccines
Vitamin D